ICU Medical Inc (ICUI) Stock Price
ICUIStock
$162.99+39.92%52W
Market Cap$4.08B
P/E5568.16x
PEG Ratio0.08
Div yield—
Beta0.89
ICUI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)17.58%
Price vs S&P 500 (4W)6.33%
PEG Ratio0.08
VGM Score48.56
P/E Ratio (Annual)5568.16x
ICUI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.91 | $2.37 | +23.81%(+$0.46) | |
| Q1 2026 | $1.75 | $1.97 | +12.46%(+$0.22) | |
| Q4 2025 | $1.69 | $1.91 | +12.80%(+$0.22) | |
| Q3 2025 | $1.43 | $2.03 | +41.63%(+$0.60) | |
| Q2 2025 | $1.50 | $2.10 | +40.00%(+$0.60) |
ICUI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.31
4.31
4.31
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ICUIICU Medical Inc | C | D | B | 1.9x | 11.9% | 39.1% | 3.5% | $162.99 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About ICU Medical Inc
ICU Medical is a pure-play infusion therapy company providing consumables, systems, and services across the full IV care continuum. The company has built top-tier market positions through strategic acquisitions, including Hospira Infusion Systems (2017) and Smiths Medical (2022), with revenues split across consumables (50%), infusion systems (30%), and vital care (20%). Over 60% of sales are generated in the United States.